2010 Annual Scientific Meeting and Exposition 2010 Annual ...

More documents

Recommendations

Info

MAY 1PostersSaturday AfternoonPO-64: 3PO-65: 3PO-66: 3PO-67: 3PO-68: 3PO-69: 3Combination Aliskiren/Amlodipine ProvidesGreater Blood Pressure Reduction than AmlodipineMonotherapy in African American Subjects withStage 2 Hypertension and Obesity or MetabolicSyndromeMyron Weinberger†, 1 J. Izzo, 2 D. Purkayastha, 3 J. Lee, 3M. Israel, 3 R. Hilkert, 3 H. Black. 4 1 Indiana UniversityMedical Center, US; 2 State University of New York atBuffalo, US; 3 Novartis Pharmaceuticals, US and 4 NewYork University, US.Aliskiren and HCTZ in Combination ProvidesImproved Blood Pressure Control Comparedwith Ramipril in Obese Patients with Stage 2Hypertension Regardless of Baseline Systolic BloodPressureAdam Whaley-Connell†, 1 D. Purkayastha, 2 Z. Ricks, 2A. Yadao, 2 J. Sowers. 1 1 University of Missouri-Columbia, US and 2 Novartis PharmaceuticalsCorporation, US.Combination Therapy with Aliskiren and HCTZDecreases Plasma Renin Activity and OxidativeStress vs Ramipril While Reducing Blood Pressurein Obese Patients with Stage 2 HypertensionAdam Whaley-Connell†, 1 J. Sowers, 1 D. Purkayastha, 2Z. Ricks, 2 A. Yadao. 2 1 University of Missouri Schoolof Medicine, US and 2 Novartis PharmaceuticalsCorporation, US.Ethnic Differences in Response to CombinationAliskiren/HCTZ vs Ramipril Monotherapy in ObesePatients with Stage 2 HypertensionAdam Whaley-Connell†, 1 D. Purkayastha, 2 Z. Ricks, 2A. Yadao, 2 J. Sowers. 1 1 University of Missouri-Columbia, US and 2 Novartis PharmaceuticalsCorporation, US.Antihypertensive Efficacy of Combination Aliskiren/HCTZ Compared to Ramipril Monotherapy inObese Stage 2 Hypertensive Patients Stratified byAgeAdam Whaley-Connell†, 1 D. Purkayastha, 2 Z. Ricks, 2A. Yadao, 2 J. Sowers. 1 1 University of Missouri-Columbia, US and 2 Novartis PharmaceuticalsCorporation, US.Combination Therapy with Aliskiren+HCTZReduces 24h Ambulatory Blood Pressure MoreEffectively than Ramipril in Obese Patients withStage 2 HypertensionAdam Whaley-Connell†, 1 D. Purkayastha, 2 Z. Ricks, 2A. Yadao, 2 J. Sowers. 1 1 University of Missouri-Columbia, US and 2 Novartis PharmaceuticalsCorporation, US.1 Pathobiology Track 2 Translational Track 3 Therapy Track114
Saturday Afternoon MAY 1PostersPO-70: 3PO-71: 3PO-72: 3PO-73: 3PO-74: 3PO-75: 3PO-76: 2Attenuation of Exercise-Induced Rise in SystolicBlood Pressure by the Direct Renin InhibitorAliskirenBryan Williams†, 1 Fabio Baschiera, 2 Peter S. Lacy, 1Jaco Botha, 2 Patrick Brunel. 2 1 Department ofCardiovascular Sciences, University of Leicester,Leicester, GB and 2 Novartis Pharma AG, Basel, CH.Initial Use of Combination Aliskiren/Valsartanis More Effective than Either ComponentMonotherapy in Elderly and Non-elderlyHypertensive PatientsSteven A. Yarows†, 1 S. Oparil, 2 S. Patel, 3 M. Wright, 4A. Yadao, 3 J. Zhang. 3 1 Chelsea Internal Medicine/IHA,MI, US; 2 UAB Vascular Biology and HypertensionProgram, AL, US; 3 Novartis PharmaceuticalsCorporation, NJ, US and 4 Novartis Pharma AG, CH.Initial Use of the Aliskiren/Valsartan Combinationis More Effective than Either ComponentMonotherapy in Hypertensive Patients with DiabetesSteven A. Yarows†, 1 S. Oparil, 2 S. Patel, 3 M. Wright, 4A. Yadao, 3 J. Zhang. 3 1 Chelsea Internal Medicine/IHA,MI, US; 2 UAB Vascular Biology and HypertensionProgram, AL, US; 3 Novartis PharmaceuticalsCorporation, NJ, US and 4 Novartis Pharma AG, CH.Initial Use of the Aliskiren/Valsartan Combinationis More Effective than Either ComponentMonotherapy in Obese and Non-Obese HypertensivePatientsSteven A. Yarows†, 1 S. Oparil, 2 S. Patel, 3 M. Wright, 4A. Yadao, 3 J. Zhang. 3 1 Chelsea Internal Medicine/IHA,MI, US; 2 UAB Vascular Biology and HypertensionProgram, AL, US; 3 Novartis PharmaceuticalsCorporation, NJ, US and 4 Novartis Pharma AG, CH.The Treatment of Renal Endothelium Dysfunctionin Scleroderma: Telmisartan Effects vs RamiprilRoman I. Yatsyshyn, Natalya G. Yatsyshyn, Yevgen M.Neyko. Ivano-Frankivsk National Medical University,Ivano-Frankivsk, UA.Telmisartan Brain Protection in CRDH Ratsas Revealed by Magnetic Resonance Imaging isBestowed to Adiponectin IncreaseFiras M. Younis, 1 Tamar Blumenfeld-Katzir, 2 TalmaRosenthal. 1 1 Tel Aviv University, Ramat Aviv, Tel Aviv,IL and 2 Tel Aviv University, Ramat Aviv, Tel Aviv, IL.Plasma Renin Efficiency, a Derived Metric ofBiomarker Response, and Its Relation to BPLowering in Hypertensive Patients on AliskirenTreatment: A Pooled Analysis Using Data from NineClinical TrialsRamesh Sarangapani†, 1 William Ebling, 2 Deborah L.Keefe. 1 1 Novartis Pharmaceuticals Corporation, EastHanover, NJ, US and 2 Emergent Insights, Newark, DE,US.1 Pathobiology Track 2 Translational Track 3 Therapy Track115
Page 1 and 2:
American Society of Hypertension201
Page 3 and 4:
Valturna offers bothsuperior BP eff
Page 5 and 6:
Figure 2: Probability of Achieving
Page 7 and 8:
potential for other drugs acting on
Page 9 and 10:
aliskiren arms were about one-third
Page 11 and 12:
As with other drugs that block angi
Page 13:
American Society of Hypertension201
Page 18:
Program Color KeyThe pages of this
Page 21 and 22:
General InformationThis program boo
Page 23 and 24:
General Information continuedHilton
Page 25 and 26:
General Information continuedASH Sc
Page 27 and 28:
General Information continuedASH Hy
Page 29 and 30:
2010 ASH Corporate MembersBoehringe
Page 31 and 32:
ASH Leadership2009-2010 Board of Di
Page 33 and 34:
Special LectureMonday, May 3, 2010,
Page 35 and 36:
Special LectureMonday, May 3, 2010,
Page 37 and 38:
2010 Abstract Reviewers continuedEr
Page 39 and 40:
Visit TEKTURNA at Booth 1100.and/or
Page 41 and 42:
5.5 HyperkalemiaIncreases in serum
Page 43 and 44:
with Pgp substrates or weak to mode
Page 45 and 46:
ASH Program at a GlanceSaturday, Ma
Page 47 and 48:
ASH Program at a GlanceMonday, May
Page 49 and 50:
Poster Category PresentationPosters
Page 51 and 52:
2010 ASH Faculty continuedJeffrey R
Page 53 and 54:
2010 ASH Faculty continuedAndrew Wh
Page 55 and 56:
2010American Societyof Hypertension
Page 57 and 58:
Saturday Afternoon MAY 1PostersPost
Page 59 and 60:
Saturday Afternoon MAY 1Sessions3:3
Page 61 and 62:
Saturday Afternoon MAY 1Sessions3:3
Page 63 and 64:
Sunday Morning MAY 2Satellite Sympo
Page 65 and 66: Sunday Morning MAY 2Sessions contin
Page 67 and 68: Sunday Morning MAY 2Sessions8:00 AM
Page 69 and 70: Sunday Morning MAY 2Sessions10:00 A
Page 71 and 72: Sunday Morning MAY 2Sessions10:00 A
Page 73 and 74: Sunday Afternoon MAY 2Sessions3:30
Page 75 and 76: Sunday Afternoon MAY 2Sessions3:30
Page 77 and 78: Sunday Afternoon MAY 2Special Sessi
Page 79 and 80: Sunday Evening MAY 2Sessions6:00 PM
Page 81 and 82: Sunday Evening MAY 2Sessions6:00 PM
Page 83 and 84: Monday Morning MAY 3Satellite Sympo
Page 85 and 86: Monday Morning MAY 3Sessions8:00 AM
Page 87 and 88: Monday Morning Afternoon MAY 21 3Po
Page 89 and 90: Monday Morning MAY 3Sessions10:00 A
Page 95 and 96: Monday Evening May 3Satellite Sympo
Page 97 and 98: Tuesday Morning May 48:45 AM LB-OR-
Page 99 and 100: Tuesday Morning May 4Sessions8:00 A
Page 101 and 102: Tuesday Morning MAY 4ASH Membership
Page 103 and 104: Tuesday Morning MAY 4Sessions10:55
Page 105 and 106: 2010American Societyof Hypertension
Page 107 and 108: Saturday Afternoon MAY 1Posters3:00
Page 109 and 110: Saturday Afternoon MAY 1PostersPO-2
Page 115: Saturday Afternoon MAY 1PostersPO-5
Page 125 and 126: Sunday Morning MAY 2PostersPosters
Page 127 and 128: Sunday Morning MAY 2Posters9:00 AM
Page 129 and 130: Sunday Morning MAY 2PostersPO-123:
Page 161 and 162: Monday Morning Afternoon May 213Pos
Page 163 and 164: Faculty Disclosure ListingGail Adle
Page 165 and 166: Faculty Disclosure Listing continue
Page 167 and 168:
Faculty Disclosure Listing continue
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
you to attend thethe Innovations Th
Page 175 and 176:
5.5 HyperkalemiaIncreases in serum
Page 177 and 178:
with Pgp substrates or weak to mode
Page 179 and 180:
Valturna (aliskiren and valsartan,
Page 181 and 182:
4 CONTRAINDICATIONSNone.5 WARNINGS
Page 183 and 184:
een reported. In a 4-day trial of v
Page 185 and 186:
7 DRUG INTERACTIONSNo drug interact
Page 187 and 188:
8.5 Geriatric UseIn 8.5the Geriatri
Page 189 and 190:
2010 ASH ExhibitorsASH Hypertension
Page 191 and 192:
ASH Hypertension Resource CenterHil
Page 193 and 194:
2010 ASH Exhibitors continuedCVRx I
Page 195 and 196:
2010 ASH Exhibitors continuedIntern
Page 197 and 198:
2010 ASH Exhibitors continuedNature
Page 199 and 200:
2010 ASH Exhibitors continuedRESPeR
Page 201 and 202:
Author IndexAAbaunza, Ricardo, 122A
Page 203 and 204:
Author IndexCastellano, Maurizio, 1
Page 205 and 206:
Author IndexGuarneri, Marco, 146Guo
Page 207 and 208:
Author IndexLekakis, John, 118, 122
Page 209 and 210:
Author IndexPittaras, Andreas, 149P
Page 211 and 212:
Author IndexTello, Susana, 109, 135
Page 213 and 214:
Hilton New York Floor PlansSecond F
Page 215 and 216:
Hilton New York Floor PlansFourth F
Page 218:
Are You 1in 3?Get the facts. Know y
show all

2010 Annual Scientific Meeting and Exposition 2010 Annual ...

Create successful ePaper yourself

Delete template?

Save as template?